For adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide 1 receptor agonists (GLP-1 RAs).

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster semaglutide-based weight‑loss injection—to Hims & Hers' digital storefront. The ...

Semaglutide has surged in popularity over the past two years, thanks to its remarkable effectiveness as a long-acting GLP-1 receptor agonist. High-profile endorsements, including from Elon Musk, have ...

In short, semaglutide can help people with diabetes improve their blood sugar and lose weight. Higher doses seem to work ...

British Columbia's Ministry of Health is limiting the sales of two more diabetes drugs to curb their off-label use for weight ...

Three studies presented today at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether ...

New and disturbing concerns about fake GLP-1 drugs are cited in a letter sent to the FDA by Tennessee officials, including Sen. Marsha Blackburn.

Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...

Pointing to Ozempic as a paradigm shift, an elite rehab center is experimenting with GLP-1s to tame many forms of addiction.

Newly published research claims those taking GLP-1 jabs are at a 37 percent lower risk of dementia than those on the ...

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.